U.S. flag

An official website of the United States government

PMC Full-Text Search Results

Items: 3

1.
Figure 3.

Figure 3. From: Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.

Cumulative incidences of relapse and non-relapse mortality. Transplanted patients are represented by blue and landmark controls by red.

Matthias Stelljes, et al. Haematologica. 2011 Jul;96(7):972-979.
2.
Figure 2.

Figure 2. From: Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.

Survival plots for corresponding intent to treat analyses (recommended allogeneic HCT, initiation of donor search and identification of a suitable allogeneic donor as defined per protocol (—); versus patients with recommended allogeneic HCT, initiation of donor search but without identification of a suitable donor as defined per protocol for patients who otherwise were eligible for an allogeneic transplant(—).

Matthias Stelljes, et al. Haematologica. 2011 Jul;96(7):972-979.
3.
Figure 1.

Figure 1. From: Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.

Survival plots for comparison groups. HCT, hematopoietic stem cell transplantation; CR1, first complete remission. Patients transplanted in CR1 (—), landmark control group (—). MUD, matched unrelated donor (—); MRD, matched related donor (—).

Matthias Stelljes, et al. Haematologica. 2011 Jul;96(7):972-979.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center